Immunome Inc
IMNM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.15B
Close$
$7.27
62.9% downside
Current Fair Value
62.9% downsideOvervalued by 62.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.15 Billion |
|---|---|
| Enterprise Value | $1.94 Billion |
| Earnings per Share | $-2.43 |
| Beta | 2.13 |
| Outstanding Shares | 113,272,931 |
Return
| Return on Equity | -48.43% |
|---|---|
| Return on Assets | -44.98% |
| Return on Invested Capital | -48.23% |
Valuation & Multiples
| P/E Ratio | -7.17 |
|---|---|
| PEG | -10.47 |
| Price to Sales | - |
| Price to Book Ratio | 4.9 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.58 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.59
Consensus analyst estimateRevenue Estimate
$222,222
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.60
Consensus analyst estimateRevenue Estimate
$153,846
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 29.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.46%▼ 104.53% |
|---|---|
| Total Invested | $11.22M▼ 99.55% |
| Investors Holding | 32▼ 179.00% |
About Immunome Inc
2,020 employees
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...